Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Vicky MakkerNicoletta ColomboAntonio Casado HerráezAlessandro D SantinEmeline ColombaDavid Scott MillerKeiichi FujiwaraSandro PignataSally Baron-HayIsabelle Ray-CoquardRonnie Shapira-FrommerKimio UshijimaJun SakataKan YonemoriYong Man KimEva M GuerraUlus A SanliMary M McCormackAlan D SmithStephen KeefeSteven BirdLea DuttaRobert J OrlowskiDomenica Lorussonull null

Published in: The New England journal of medicine (2022)

Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer. (Funded by Eisai and Merck Sharp and Dohme [a subsidiary of Merck]; Study 309-KEYNOTE-775 ClinicalTrials.gov number, NCT03517449.).

Keyphrases

endometrial cancer
free survival
advanced non small cell lung cancer
locally advanced
clinical trial
squamous cell carcinoma
radiation therapy
study protocol